CL2023002780A1 - Fabricación de un producto farmacéutico cristalino - Google Patents

Fabricación de un producto farmacéutico cristalino

Info

Publication number
CL2023002780A1
CL2023002780A1 CL2023002780A CL2023002780A CL2023002780A1 CL 2023002780 A1 CL2023002780 A1 CL 2023002780A1 CL 2023002780 A CL2023002780 A CL 2023002780A CL 2023002780 A CL2023002780 A CL 2023002780A CL 2023002780 A1 CL2023002780 A1 CL 2023002780A1
Authority
CL
Chile
Prior art keywords
manufacturing
pharmaceutical product
crystalline pharmaceutical
particles
crystalline
Prior art date
Application number
CL2023002780A
Other languages
English (en)
Inventor
Harteva Merja
Staffans Anna
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61599196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2023002780(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of CL2023002780A1 publication Critical patent/CL2023002780A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención actual se refiere a partículas cristalinas de N-((S)-1-(3-(3-cloro-4-ciano-fenil)-1H-pirazol-1-il)-propan-2-il)-5-(1-hidroxi-etil)-1H-pirazol-3-carboxamida (I) que tienen un área de superficie específica (SSA) en el intervalo desde alrededor de 8 hasta alrededor de 16 m2/g, preferiblemente desde alrededor de 10 hasta alrededor de 15 m2/g, y al método para la preparación de tales partículas. El Compuesto (I) es un modulador del receptor de andrógeno (AR) potente que es útil como un medicamento por ejemplo en el tratamiento del cáncer de próstata.
CL2023002780A 2017-03-07 2023-09-20 Fabricación de un producto farmacéutico cristalino CL2023002780A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20175202 2017-03-07

Publications (1)

Publication Number Publication Date
CL2023002780A1 true CL2023002780A1 (es) 2024-01-26

Family

ID=61599196

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019002540A CL2019002540A1 (es) 2017-03-07 2019-09-04 Fabricación de un producto farmacéutico cristalino.
CL2023002780A CL2023002780A1 (es) 2017-03-07 2023-09-20 Fabricación de un producto farmacéutico cristalino

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019002540A CL2019002540A1 (es) 2017-03-07 2019-09-04 Fabricación de un producto farmacéutico cristalino.

Country Status (12)

Country Link
US (1) US11168058B2 (es)
EP (1) EP3592732A1 (es)
JP (1) JP7157071B2 (es)
CN (1) CN110382467A (es)
AU (1) AU2018229817B2 (es)
BR (1) BR112019018458A2 (es)
CA (1) CA3055019A1 (es)
CL (2) CL2019002540A1 (es)
EA (1) EA201992103A1 (es)
MX (1) MX2019010452A (es)
UA (1) UA126071C2 (es)
WO (1) WO2018162793A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515040A (ja) 2018-02-27 2021-06-17 サンド・アクチエンゲゼルシヤフト ダロルタミドの結晶形態ｉｉ
AU2020300043A1 (en) 2019-07-02 2022-01-06 Orion Corporation Pharmaceutical composition of darolutamide
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
WO2022144926A1 (en) * 2020-12-31 2022-07-07 Msn Laboratories Private Limited, R&D Center Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide
WO2023161458A1 (en) 2022-02-28 2023-08-31 Química Sintética, S.A. Crystalline form of darolutamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513622A (ja) 2005-10-27 2009-04-02 ルピン・リミテッド ロサルタンの医薬製剤
EP2168601B1 (en) 2007-05-28 2013-08-21 Mitsubishi Shoji Foodtech Co., Ltd Spherical mannitol crystal particle
CA2755314A1 (en) * 2009-03-12 2010-09-16 Medichem, S.A. New crystals of a benzoylbenzeneacetamide derivative
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
AU2012245106B2 (en) * 2011-04-21 2016-09-08 Orion Corporation Androgen receptor modulating carboxamides
JP2014515764A (ja) * 2011-05-04 2014-07-03 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎ウイルス阻害剤の調製法
PL3250554T3 (pl) 2015-01-30 2022-09-19 Orion Corporation Pochodna karboksyamidu i jej diastereomery w stabilnej postaci krystalicznej
SI3495352T1 (sl) 2016-08-26 2021-08-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Kristalinične oblike antagonista androgenskih receptorjev, postopek njihove priprave in njihova uporaba

Also Published As

Publication number Publication date
US11168058B2 (en) 2021-11-09
UA126071C2 (uk) 2022-08-10
JP7157071B2 (ja) 2022-10-19
JP2020510018A (ja) 2020-04-02
CL2019002540A1 (es) 2020-01-31
WO2018162793A1 (en) 2018-09-13
US20200039940A1 (en) 2020-02-06
KR20190126111A (ko) 2019-11-08
BR112019018458A2 (pt) 2020-04-14
EP3592732A1 (en) 2020-01-15
AU2018229817B2 (en) 2021-09-30
MX2019010452A (es) 2019-10-15
CA3055019A1 (en) 2018-09-13
CN110382467A (zh) 2019-10-25
AU2018229817A1 (en) 2019-10-24
EA201992103A1 (ru) 2020-01-24

Similar Documents

Publication Publication Date Title
CL2023002780A1 (es) Fabricación de un producto farmacéutico cristalino
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
MX2021007184A (es) Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan.
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
CL2019000397A1 (es) Proceso para preparar el compuesto n-((s)-1-(3-(3-cloro -4-cianofenil)-1h-pirazol-1-il)-5-(1-hidroxi-etil)-1h-pirazol-3-carboxamida de la formula (1a).(divisional solicitud 201702491)
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MX2022001656A (es) Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
IN2015DN00528A (es)
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
EP4219507A3 (en) Thienopyrimidinone nmda receptor modulators and uses thereof
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
CL2016001763A1 (es) Antagonistas selectivos de nr2b
PH12015502676A1 (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
PL3199171T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania degeneracyjnym zaburzeniom neurologicznym, zawierająca, jako składnik aktywny, mieszaninę ekstraktu z kory korzenia piwonii drzewiastej, korzenia dzięgielu dahuryjskiego i korzenia przewiercienia lub ich frakcję
SA519410097B1 (ar) P2x7 مشتقات رباعي هيدروكوينولين كمعارضات مستقبل
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
MX2019012116A (es) Agentes antifungicos utilizados en combinacion.
JOP20190054B1 (ar) مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EP3659584A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISORDERS, CONTAINING HDL-APOM-S1P AS ACTIVE INGREDIENT
EA201791450A1 (ru) 3,5-диаминопиразоловые ингибиторы киназы
EP3785715A4 (en) Pharmaceutical composition comprising ibrutinib as effective ingredient for preventing or treating degenerative brain disease